Sodium phenylbutyrate/tauroursodeoxycholic acidAlternative Names: AMX 0035; Tauroursodeoxycholic acid/sodium phenylbutyrate
Latest Information Update: 21 Jan 2016
At a glance
- Originator Amylyx Pharmaceuticals
- Class Antidementias
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis